| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/070674370905400906 |
| P698 | PubMed publication ID | 19751550 |
| P2093 | author name string | Susan E Abbey | |
| Sanjeev Sockalingam | |||
| P2860 | cites work | A rating scale for depression | Q24564540 |
| The CES-D Scale: A Self-Report Depression Scale for Research in the General Population | Q26778378 | ||
| Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction | Q27477533 | ||
| The hospital anxiety and depression scale | Q27860968 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Psychiatric comorbidity among hepatitis C-positive patients | Q30308359 | ||
| Quetiapine-induced leucopenia and thrombocytopenia | Q33377744 | ||
| Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter | Q47815976 | ||
| Psychiatric complications of long-term interferon alfa therapy | Q48215043 | ||
| Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol | Q48289993 | ||
| Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain | Q48802606 | ||
| Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. | Q50570213 | ||
| Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. | Q50571205 | ||
| Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. | Q50571366 | ||
| Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. | Q50571817 | ||
| Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. | Q50571918 | ||
| Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. | Q50572020 | ||
| Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. | Q50573947 | ||
| A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. | Q50574234 | ||
| Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. | Q50580085 | ||
| A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. | Q50583478 | ||
| Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. | Q50953377 | ||
| Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. | Q50971743 | ||
| Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. | Q51090450 | ||
| Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. | Q51893888 | ||
| High frequency of unrecognized mental disorders in HCV-infected patients. | Q51895436 | ||
| Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. | Q51921166 | ||
| Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. | Q51932157 | ||
| Prevalence of hepatitis C among psychiatric patients in the public sector. | Q51951423 | ||
| Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. | Q51969974 | ||
| Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy | Q56767259 | ||
| Morbidity of chronic hepatitis C as seen in a tertiary care medical center | Q33498295 | ||
| Cytokines, "depression due to a general medical condition," and antidepressant drugs | Q33708167 | ||
| Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review | Q33930192 | ||
| Neuropsychiatric adverse effects of interferon-alpha: recognition and management | Q34081783 | ||
| Major depressive disorder in hepatitis C: an open-label trial of escitalopram | Q34084151 | ||
| Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study | Q34725432 | ||
| Interferon alpha (IFNalpha) and psychiatric syndromes: a review | Q34790180 | ||
| Bupropion for treatment of interferon-induced depression | Q35776758 | ||
| Drug-induced depression: a systematic review to inform clinical practice | Q35796768 | ||
| Interferon-induced depression: prevalence and management | Q36055669 | ||
| Depression following pegylated interferon-alpha: characteristics and vulnerability | Q36183715 | ||
| Treatment of recurrent hepatitis C after liver transplantation | Q36197584 | ||
| Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory | Q36274123 | ||
| Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. | Q36619642 | ||
| Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis | Q38499002 | ||
| Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. | Q42959380 | ||
| Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. | Q43425647 | ||
| Paroxetine for the prevention of depression induced by high-dose interferon alfa | Q43556890 | ||
| Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system | Q43859445 | ||
| Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. | Q43942974 | ||
| Spectrum of disease in U.S. veteran patients with hepatitis C. | Q44074835 | ||
| Psychiatric disorders among veterans with hepatitis C infection | Q44081498 | ||
| Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office | Q44097379 | ||
| A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. | Q44194141 | ||
| Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups | Q44286530 | ||
| Mirtazapine for the treatment of interferon-induced psychopathology | Q44714330 | ||
| Plasma levels of citalopram in depressed patients with hepatitis C. | Q44717425 | ||
| Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms | Q44858854 | ||
| Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. | Q44971783 | ||
| IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity | Q45115322 | ||
| Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression | Q45227683 | ||
| Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. | Q45234522 | ||
| Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser | Q45238711 | ||
| Depression during therapy with interferon alpha--how long should an antidepressant treatment last? | Q45296987 | ||
| Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection | Q45333052 | ||
| Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha | Q45405547 | ||
| Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus | Q45730010 | ||
| Depressive symptoms and physical/mental functioning with interferon/ribavirin treatment of posttransplant recurrent hepatitis C. | Q46234381 | ||
| Sertraline- and mirtazapine-induced severe neutropenia | Q46580906 | ||
| Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment | Q46646985 | ||
| Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. | Q46735615 | ||
| Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis | Q46751582 | ||
| HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment | Q46951192 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 614-625 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Canadian Journal of Psychiatry | Q5030253 |
| P1476 | title | Managing depression during hepatitis C treatment | |
| P478 | volume | 54 |
| Q37547057 | A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz |
| Q30372214 | Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment. |
| Q34077806 | Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City. |
| Q40599927 | Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions. |
| Q35087836 | Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. |
| Q47888797 | Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression |
| Q35885462 | Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China |
| Q36067334 | Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance |
| Q33390478 | Individualisation of antiviral therapy for chronic hepatitis C. |
| Q56917730 | Influence of healthcare-associated factors on the efficacy of hepatitis C therapy |
| Q39256580 | Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt |
| Q34538771 | Management of Hepatitis C Antiviral Therapy Adverse Effects |
| Q42084129 | Management of Psychiatric Disease in Hepatitis C Treatment Candidates |
| Q33956478 | Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response |
| Q26798477 | Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications |
| Q40671808 | Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]. |
| Q33708662 | Psychiatric clearance for patients started on interferon-alpha-based therapies |
| Q34721628 | Psychiatric treatment considerations with direct acting antivirals in hepatitis C |
| Q37349893 | TLR4 signaling in VTA dopaminergic neurons regulates impulsivity through tyrosine hydroxylase modulation |
| Q92810474 | The role of circulatory systemic environment in predicting interferon-alpha-induced depression: The neurogenic process as a potential mechanism |
| Q34962752 | Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders |
Search more.